Market Research Logo

Coronaviridae Infections - Pipeline Review, H2 2016

Coronaviridae Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Coronaviridae Infections - Pipeline Review, H2 2016’, provides an overview of the Coronaviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Coronaviridae Infections
    • The report reviews pipeline therapeutics for Coronaviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Coronaviridae Infections therapeutics and enlists all their major and minor projects
    • The report assesses Coronaviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Coronaviridae Infections
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Coronaviridae Infections
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Coronaviridae Infections pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Coronaviridae Infections Overview
    Therapeutics Development
    Pipeline Products for Coronaviridae Infections - Overview
    Pipeline Products for Coronaviridae Infections - Comparative Analysis
    Coronaviridae Infections - Therapeutics under Development by Companies
    Coronaviridae Infections - Therapeutics under Investigation by Universities/Institutes
    Coronaviridae Infections - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Coronaviridae Infections - Products under Development by Companies
    Coronaviridae Infections - Products under Investigation by Universities/Institutes
    Coronaviridae Infections - Companies Involved in Therapeutics Development
    AstraZeneca Plc
    CEL-SCI Corporation
    GeneCure LLC
    Gilead Sciences, Inc.
    Hemispherx Biopharma, Inc.
    Humabs BioMed SA
    Inovio Pharmaceuticals, Inc.
    Kineta, Inc.
    Nanotherapeutics, Inc.
    NanoViricides, Inc.
    Novavax, Inc.
    Organic Vaccines
    Phelix Therapeutics, LLC
    Planet Biotechnology Inc.
    Protein Sciences Corporation
    Regeneron Pharmaceuticals Inc
    Coronaviridae Infections - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    CEL-1000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    D-3252 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FBR-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FDX-000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-5734 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INO-4500 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon alfa-n3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon beta-1a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KIN-1400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LCA-60 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome coronavirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome coronavirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome coronavirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ML-188 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Coronavirus Infection - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for SARS Virus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RBD-219N1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-3048 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    REGN-3051 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAB-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SARS (virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    severe acute respiratory syndrome vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Viral Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit 3CLpro for Coronavirus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SSYA-10001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Coronaviridae Infections - Dormant Projects
    Coronaviridae Infections - Discontinued Products
    Coronaviridae Infections - Product Development Milestones
    Featured News & Press Releases
    Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment
    Aug 08, 2016: GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine
    Jan 20, 2016: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection as a Treatment of Middle East Respiratory Syndrome
    Nov 19, 2015: GeneOne Life Science and Inovio Pharmaceuticals’ MERS Vaccine Approved for First-in-Human Study
    Oct 19, 2015: Inovio and Partner Advance MERS Vaccine
    Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome
    Jul 28, 2015: PNAS Paper Details Efficacy Of A Potent, Fully Human Antibody For The Treatment Of MERS
    Jul 15, 2015: Hemispherx Biopharma Europe Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection for Treatment of Middle East Respiratory Syndrome
    Jun 22, 2015: MERS coronavirus: Candidate vaccine gears up for clinical trials
    Jun 04, 2015: Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections
    Jun 16, 2014: Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)
    Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus
    Jun 06, 2013: Novavax Produces New Vaccine Candidate To Fight MERS-CoV Infection
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Coronaviridae Infections, H2 2016
    Number of Products under Development for Coronaviridae Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Coronaviridae Infections - Pipeline by AstraZeneca Plc, H2 2016
    Coronaviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016
    Coronaviridae Infections - Pipeline by GeneCure LLC, H2 2016
    Coronaviridae Infections - Pipeline by Gilead Sciences, Inc., H2 2016
    Coronaviridae Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016
    Coronaviridae Infections - Pipeline by Humabs BioMed SA, H2 2016
    Coronaviridae Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
    Coronaviridae Infections - Pipeline by Kineta, Inc., H2 2016
    Coronaviridae Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
    Coronaviridae Infections - Pipeline by NanoViricides, Inc., H2 2016
    Coronaviridae Infections - Pipeline by Novavax, Inc., H2 2016
    Coronaviridae Infections - Pipeline by Organic Vaccines, H2 2016
    Coronaviridae Infections - Pipeline by Phelix Therapeutics, LLC, H2 2016
    Coronaviridae Infections - Pipeline by Planet Biotechnology Inc., H2 2016
    Coronaviridae Infections - Pipeline by Protein Sciences Corporation, H2 2016
    Coronaviridae Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Coronaviridae Infections - Dormant Projects, H2 2016
    Coronaviridae Infections - Dormant Projects (Contd..1), H2 2016
    Coronaviridae Infections - Dormant Projects (Contd..2), H2 2016
    Coronaviridae Infections - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Coronaviridae Infections, H2 2016
    Number of Products under Development for Coronaviridae Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report